[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,80,109,157,179,208,230],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054204","evaluation-of-an-electric-stimulator-for-medical-use-by-personal-lrtpm1-for-visual-function-in-early-to-intermediate-dry-age-related-macular-degeneration-100054204",false,"NCT07700147","Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration","A Multicenter, Randomized, Double-Blind, Sham-Controlled, Parallel-Group Exploratory Clinical Trial Evaluating the Efficacy and Safety of an Electric Stimulator for Medical Use by Personal (LRTPM1) in Improving Visual Function in Patients With Early to Intermediate Dry Age-Related Macular Degeneration","Inclusion Criteria:\n\n1. Participants aged 50 years or older\n2. Participants diagnosed with early or intermediate dry age-related macular degeneration\n3. Participants with best corrected visual acuity measured by the ETDRS visual acuity chart of 20\u002F200 or better and 20\u002F30 or worse\n4. Participants who have voluntarily decided to participate in the study and have provided written informed consent.\n\nExclusion Criteria:\n\n1. Participants with atrophy involving the foveal center with a diameter of 175 micrometers or greater in at least one eye, as observed by fundus examination or fundus autofluorescence imaging\n2. Participants with exudative age-related macular degeneration in at least one eye, as observed by fundus examination or optical coherence tomography (OCT)\n3. Participants with a history of intraocular injection therapy or macular laser treatment, including focal laser photocoagulation or photodynamic therapy\n4. Participants with retinal or choroidal diseases other than early or intermediate age-related macular degeneration that may affect the study results, including diabetic retinopathy, retinal artery occlusion, retinal vein occlusion, central serous chorioretinopathy, optic neuritis, or uveitis\n5. Participants who have undergone vitrectomy due to retinal disease, or cataract surgery within 1 month prior to screening\n6. Participants with ocular media opacity or other conditions that, in the investigator's opinion, may make ophthalmic imaging difficult to interpret, including cataract, vitreous opacity, or vitreous hemorrhage\n7. Participants with uncontrolled chronic systemic diseases, including diabetes mellitus or chronic kidney disease, or a history of malignancy, except for cases with no recurrence within the past 5 years and no history of chemotherapy\n8. Participants with autoimmune diseases, including Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, or Graves' disease\n9. Participants with severe hearing impairment, sensory abnormalities, or cognitive impairment that may make it difficult to properly perform the study procedures or recognize or report adverse events\n10. Participants who are hypersensitive to orbital nerve stimulation and are unable to receive treatment\n11. Participants with a history of drug or alcohol abuse\n12. Participants diagnosed with psychiatric disorders, including depression, schizophrenia, bipolar disorder, or dementia\n13. Participants who have participated in another clinical trial within 30 days prior to screening\n14. Participants who are considered to have other contraindications to use of the investigational medical device, including underlying cardiac disease, seizure-related disorders, implanted metal or electronic devices in the head or neck area including deep brain stimulators, unexplained pain, implanted or wearable pacemakers, or other conditions listed in the product precautions and contraindications. Dental implants are exempt.\n15. Participants who, in the opinion of the investigator, are deemed inappropriate for participation in the study\n16. Female participants of childbearing potential who do not agree to use medically accepted contraception during the study period. Medically accepted methods of contraception include condoms, oral contraceptives used consistently for at least 3 months, injectable or implantable contraceptives, or intrauterine devices.","ALL","50 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of an electric stimulator for medical use by personal (LRTPM1) in patients with early to intermediate dry age-related macular degeneration.\n\nThe main questions this study aims to answer are:\n\n* Does the investigational device improve visual function, as assessed by best corrected visual acuity and contrast sensitivity?\n* What treatment-emergent adverse events occur during the study?\n\nParticipants will:\n\n* Be randomized to receive either active stimulation or sham stimulation\n* Apply the assigned investigational device at home once daily for 30 minutes over a 12-week treatment period\n* Visit the study site for eye examinations and safety assessments\n* Return for a follow-up visit 4 weeks after the end of treatment",[26,27],"Dry Age-Related Macular Degeneration","AMD",[29,30,31,32],"Neurostimulation","Electrical stimulation","ES","stimulation","NOT_YET_RECRUITING","2026-07-07",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":20},"2026-07-09",{"date":41,"type":20},"2028-04-17",{"name":43,"class":44},"Nu Eyne Co., Ltd.","INDUSTRY",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":4,"leadSponsor":76,"locationsCount":79},"100165906","cell-collection-to-study-eye-diseases-100165906","NCT01432847","Cell Collection to Study Eye Diseases","Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls","* INCLUSION CRITERIA:\n\nTo be eligible, participants must meet the following inclusion criteria.\n\n1. Have the ability to understand and sign an informed consent or have a parent\u002Flegal guardian to do so if they are minor children or have a legally authorized representative if they are adults without consent capacity.\n2. Participant meets one of the following criteria:\n\n   1. Participant has been diagnosed with an ocular condition of interest including but not limited to: degenerative retinal diseases, optic atrophy, microphthalmia\u002Fanophthalmia, ciliopathy, and other ocular developmental or degenerative conditions.\n   2. Participant is free of eye diseases and could serve as an unaffected control. Participant's age, sex, and ethnicity must match an existing participant with one of the eye diseases under study. Control participants matched to AMD participants must not have drusen greater than 63 microns in size.\n3. Adult participant is able to provide a punch skin biopsy and 30 mL of peripheral venous blood OR child participant is able to provide a punch skin biopsy and the lesser of 5 mL\u002Fkg or 30 mL of peripheral venous blood. Healthy, unaffected children will only have one skin punch biopsy done 3mm or less in size. In affected participants, an additional punch may be gathered if the initial sample does not contain adequate cells. This will be taken from children ages seven years and older. Sampling of ten occipital hairs and\u002For saliva may be pursued at the investigator's discretion. Participants not able to provide a skin biopsy or blood sample may opt to provide 100-200 ml of fresh urine. As a rule, samples will be collected on non-sedated\u002Fanesthetized participants. Sedation\u002Fanesthesia will NOT be used solely for the purpose of sample collection. In rare instances where a minor requires sedation for another medically indicated procedure, samples may be collected at the time of sedation\u002Fanesthesia. Because young children may not be able to cooperate with sample collection, those unable to provide a skin biopsy, urine sample or a blood sample may be excluded from the study, based on the judgment of the examining investigator.\n4. Participant meets one of the following criteria:\n\n   1. Participant affected with an ocular condition is one year of age or older.\n   2. Participant affected with Best disease, L-ORD, or AMD is 18 years of age or older.\n   3. Unaffected participant is seven years of age or older and willing and able to provide assent.\n\nEXCLUSION CRITERIA:\n\nA participant is not eligible if any of the following exclusion criteria are present.\n\n1. Participant is unable to comply with study procedures.\n2. Participant has a systemic disease that, in the opinion of the investigator, compromises the ability to provide adequate samples. Examples of co-existing diseases that would exclude a participant include a bleeding diathesis or a genetic susceptibility to infections, particularly cutaneous infections.\n\nADDITIONAL CRITERIA FOR CLNICAL-GRADE CELL LINE GENERATION:\n\nThe additional eligibility criteria must be met for participants donating samples for the generation of clinical-grade cell lines.\n\nInclusion Criteria\n\n1. Participant must be greater than 18 years of age, as of the date of enrollment. There is no upper age limit for donor enrollment.\n2. Participant is able to provide a punch skin biopsy and 200 ml of peripheral venous blood.\n3. Participant is willing and eligible to co-enroll in NEI protocol 15-EI-0128.\n\nExclusion Criteria\n\n1. Participant has medical history that includes any of the following:\n\n   1. Thrombocytopenia or other blood dyscrasias\n   2. Bleeding diathesis\n   3. Antibiotic use within the prior 48 hours\n   4. Active cancer or history of cancer within the past five years\n   5. History of exposure to transfusion transmitted diseases including HIV and hepatitis B and C as defined by the Standards for Blood\n\n      Banking and Transfusion Services, American Association of Blood Banks.\n   6. Travel to an area where malaria is endemic as defined by the CDC (www.cdc.gov\u002Ftravel)\n   7. At risk for the possible transmission of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) as described in the FDA Guidance for Industry, January 9, 2002, \"Revised Preventive Measures to Reduce the Possible Risk of Transfusion of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) by Blood and Blood Products\"\n2. Participant is currently febrile (temperature \\> 38 degrees C)\n3. Participant has Hemoglobin level:\n\n   * African American women \\\u003C11.5 grams\u002FdL\n   * Other women \\\u003C 12.0 grams\u002FdL\n   * Men \\\u003C12.5 grams\u002FdL\n4. Participant has low hematocrit (HCT):\n\n   * African American women \\\u003C 34%\n   * Other women \\\u003C36%\n   * Men \\\u003C38%\n5. Participant has Platelets \\\u003C150 x 103\u002FmicroL\n6. Participant has Absolute neutrophil count \\\u003C1.0 x 103\u002FmicroL.\n7. Participant has positive tests for blood borne pathogens (as required by the Standards for Blood Banks and Transfusion Services, American Association of Blood Banks. The currently required tests include anti-HIV1\u002F2, anti-HCV, anti-HBc, Anti-HTLV I\u002FII, anti-T. Cruzi, HBsAg, syphilis, and molecular testing for West Nile virus, HCV, HBV, and HIV-1).",true,"1 Day","120 Years",{"count":57,"type":20},930,"OBSERVATIONAL","Background:\n\n\\- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases. However, cells collected from hair follicles, skin, saliva, urine, and blood can be used for research. Researchers want to collect cells from people with Best disease, L-ORD, and AMD, and compare their cells with those of healthy volunteers.\n\nObjectives:\n\n\\- To collect hair, skin, saliva, urine, and\u002For blood samples to study three eye diseases that affect the retina: Best disease, L-ORD, and AMD.\n\nEligibility:\n\n* Individuals affected with ocular condition is one year of age or older.\n* Individuals affected with Best disease, L-ORD, or AMD is 18 years of age or older.\n* Unaffected individuals are seven years of age or older.\n\nDesign:\n\n* The study requires one visit to the National Eye Institute.\n* Participants will be screened with a medical and eye disease history. They may also have an eye exam.\n* Participants will provide a hair sample, saliva sample, urine sample, blood sample, and\u002For a skin biopsy. The hair will be collected from the back of the head, and the skin will be collected from the inside of the upper arm.",[61,27,62,63],"Retinal Disease","Retinal Degeneration","Retinitis Pigmentosa",[65,66,67,68,62,69,27],"Best Disease","Late-Onset Retinal Degeneration (L-ORD)","Age-Related Macular Degeneration (AMD)","Natural History","Age-Related Macular Degeneration","RECRUITING","2026-06-18",{"date":73,"type":37},"2026-06-22",{"date":75,"type":37},"2011-09-07",{"name":77,"class":78},"National Eye Institute (NEI)","NIH",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":53,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":87,"targetDuration":89,"studyType":58,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100615388","retinal-clinical-assessment-with-ai-derived-quantitative-information-100615388","NCT07291960","Retinal Clinical Assessment With AI-derived Quantitative Information","AI-derived Retinal Quantification Versus Routine Clinical Interpretation in Ophthalmic Assessment: a Randomized Controlled Trial","Inclusion Criteria:\n\nClinician Participants (Report Writers)\n\n1. Board-certified ophthalmologists or ophthalmology trainees (registrars or fellows) with clinical experience in interpreting fundus images.\n2. Capable of independently completing retinal clinical reports based on fundus photography.\n3. Willing and able to participate in the study tasks (report writing) under assigned study conditions.\n4. Able to provide informed consent.\n\nExpert Evaluators (Outcome Assessors)\n\n1. Senior ophthalmologists with at least 5 years of post-certification clinical experience.\n2. Not involved in the report-writing stage of the study.\n3. Willing to evaluate de-identified reports across predefined quality dimensions.\n4. Able to provide informed consent.\n\nFundus Images (Data Inputs)\n\n1. Retinal fundus photographs of sufficient quality for clinical interpretation.\n2. Images representing a range of common retinal findings (normal or abnormal).\n3. Previously collected, de-identified images with no patient-identifiable information.\n\nExclusion Criteria:\n\nClinician Participants\n\n1. Lack of experience in interpreting fundus images (e.g., interns, medical students).\n2. Prior involvement in the development, training, or validation of the AI system being tested.\n3. Inability to complete reporting tasks due to time constraints or technical limitations.\n4. Any condition that may interfere with ability to perform study tasks (e.g., prolonged absence).\n\nExpert Evaluators\n\n1. Participation in the intervention or control reporting arms.\n2. Prior exposure to or involvement in development of the AI system.\n3. Any conflict of interest affecting impartiality of report quality evaluation.\n\nFundus Images\n\n1. Poor-quality images with insufficient clarity for interpretation.\n2. Images containing artifacts or cropping that prevent accurate segmentation or assessment.\n3. Images with any remaining patient identifiers (excluded to maintain confidentiality).",{"count":88,"type":20},29,"21 Days","This randomized controlled trial evaluates whether providing clinicians with AI-derived quantitative retinal information improves the quality and efficiency of retinal clinical assessment. Participating ophthalmologists and ophthalmology trainees will be randomly assigned to one of two groups. The intervention group will write clinical reports with access to automated quantitative measurements generated from fundus image analysis, including multiple retinal structural and vascular biomarkers. The control group will complete the same reporting tasks using only the original fundus images without AI-generated quantitative information.\n\nAll reports produced by both groups will be de-identified and independently evaluated by a separate panel of senior ophthalmologists who are blinded to group allocation. The expert evaluators will assess report accuracy, completeness, clarity, and overall clinical quality using predefined scoring criteria. The study aims to determine whether access to quantitative retinal biomarkers enhances clinicians' reporting performance and reduces reporting time during retinal assessment tasks.",[92,93,27,94,95,96,97,98],"no Obvious Abnormalities","Diabetic Retinopathy (DR)","Cup-to-disc Ratio Bigger Than 0.5","Pathological Myopia","Macular Hole","Epiretinal Membrane","Retinal Vein Occlusion (RVO)","2026-04-28",{"date":101,"type":37},"2026-04-29",{"date":103,"type":20},"2026-04-15",{"date":105,"type":20},"2026-05-15",{"name":107,"class":108},"Beijing Tongren Hospital","OTHER",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":122,"conditions":123,"keywords":129,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100470574","phase-3-pivotal-2-study-of-rgx-314-gene-therapy-in-participants-with-namd-100470574","NCT05407636","Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD","ASCENT","Inclusion Criteria:\n\n1. Age ≥ 50 years and ≤ 89 years\n2. An ETDRS BCVA letter score between ≤ 78 and ≥ 40 in the study eye\n3. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in the study eye previously treated with anti-VEGF\n4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye\n5. Willing and able to provide written, signed informed consent for this study\n6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at study entry\n\nInclusion Criteria (Bilateral Treatment Substudy)\\*:\n\n1. An ETDRS BCVA letter score between ≤ 83 and ≥ 40 in both eyes\n2. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in both eyes\n3. Must be pseudophakic (at least 12 weeks postcataract surgery) in both eyes\n4. Willing and able to provide written, signed informed consent for this study\n5. Newcomers must have active disease in the study eye; crossover participants must have active disease in the eye not treated in the main study\n\nExclusion Criteria:\n\n1. CNV or macular edema in the study eye secondary to any causes other than AMD\n2. Subfoveal fibrosis or atrophy in the study eye\n3. Any condition in the investigator's opinion that could limit VA improvement in the study eye\n4. Advanced glaucoma or history of secondary glaucoma in the study eye\n5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months\n6. History of intraocular surgery in the study eye within 12 weeks prior to randomization\n7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6\n8. Prior treatment with gene therapy\n\nExclusion Criteria (Bilateral Treatment Substudy)\\*:\n\n1. CNV or macular edema in either eye secondary to any causes other than AMD\n2. Subfoveal fibrosis or atrophy in either eye\n3. Any condition in the investigator's opinion that could limit VA improvement in either eye\n4. Advanced glaucoma or history of secondary glaucoma in either eye\n5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months\n6. History of intraocular surgery in either eye within 12 weeks prior to randomization\n7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6.\n8. Prior treatment with gene therapy (\\*) For previously treated crossover participants, criteria apply to the eye not treated in the main study only.\n\nNote: Other inclusion\u002Fexclusion criteria apply","89 Years",{"count":119,"type":20},714,[121],"PHASE3","ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.",[27,124,125,126,127,128],"nAMD","Wet Age-related Macular Degeneration","wAMD","WetAMD","CNV",[69,130,131,132,133,62,134,135,136,137,138,139,140,141,142,143,144,145,146,27,147],"Neovascular Age-Related Macular Degeneration","Macular Degeneration","Wet Macular Degeneration","Choroidal Neovascularization","Retinal Diseases","Eye Diseases","Ranibizumab","Aflibercept","Angiogenesis Inhibitors","Angiogenesis Modulating Agents","Growth Substances","Physiological Effects of Drugs","Growth Inhibitors","Antineoplastic Agents","Gene Therapy","Anti-vascular endothelial grown factory therapy","Anti-VEGF therapy","wet AMD",{"date":149,"type":37},"2026-04-20",{"date":151,"type":37},"2022-01-13",{"date":153,"type":20},"2027-11",{"name":155,"class":44},"AbbVie",181,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":79},"100613682","phase-3-a-clinical-trial-evaluating-the-efficacy-and-safety-of-sanhuang-jingshiming-pills-in-the-treatment-of-namd-100613682","NCT07269769","A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD","A Phase III , Randomized, Double-blind, Placebo-Controlled, Ranibizumab Injection Loading, Multicenter Clinical Trial Comparing the Efficacy and Safety of Sanhuang Jingshiming Pills in Subjects With nAMD","Inclusion Criteria:\n\n1. Aged 50 to 85 years old (inclusive of 50 and 85 years old)\n2. Meets the Western medical diagnostic criteria for neovascular age-related macular degeneration\n3. Meets the TCM syndrome differentiation criteria for Qi-Yin Deficiency with Phlegm-Blood Stasis Intermingling Syndrome\n4. The study eye is diagnosed with nAMD and the disease is in the active phase\n5. BCVA of the study eye assessed by the ETDRS visual acuity chart ranges from 25 to 78 letters\n6. Voluntarily participates in the clinical trial, signs the ICF, and is able to understand and comply with the trial procedures\n\nExclusion Criteria:\n\n1. The study eye is complicated with pathologic myopia, high myopia, or secondary MNV caused by other definite diseases, glaucoma, diabetic retinopathy , retinal artery\u002Fvein occlusion , optic neuropathy (optic neuritis, optic atrophy, papilledema), macular hole, acute phase of intraocular inflammation, or other ocular diseases\n2. Patients with pure PED in the study eye\n3. Patients with subfoveal structural destruction or subfoveal fibrosis\u002Fscars\u002FRPE tear\u002FGA in the study eye\n4. Patients whose FP of the study eye shows a total macular lesion area \\> 9 disc areas (total lesion area is defined as the sum of the areas of MNV, atrophy, scars, and fibrosis); or patients whose FP of the study eye shows a maximum macular hemorrhage area \\> 4 disc areas\n5. Patients with CRT ≥ 700 μm in the study eye as assessed by OCT\n6. Patients with opaque refractive media (e.g., vitreous hemorrhage, cataract) in the study eye precluding adequate visualization of the fundus, or with a history of vitrectomy\n7. Patients planning to undergo any intraocular surgery on the study eye during the trial period\n8. Patients who received pharmacologic treatment for nAMD within 2 weeks prior to randomization\n9. Patients who received intravitreal anti-vascular endothelial growth factor therapy on the study eye within 4 months prior to randomization\n10. Patients who received photodynamic therapy , laser photocoagulation, macular surgery, transpupillary thermotherapy , or corticosteroid therapy on the study eye within 6 months prior to randomization\n11. Patients who underwent any intraocular or periocular surgery (excluding eyelid surgery) on the study eye within 3 months prior to randomization\n12. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg while on regular antihypertensive medication)\n13. History of major cardiovascular or cerebrovascular diseases, including but not limited to: ① history of myocardial infarction (MI), coronary angioplasty or bypass surgery, valvular heart disease or valvular repair, clinically significant and treatment-requiring arrhythmia, unstable angina, transient ischemic attack (TIA), cerebrovascular accident (CVA), etc., within 6 months prior to randomization; ② congestive heart failure (CHF) with New York Heart Association (NYHA) classification of Grade Ⅲ or Ⅳ\n14. Laboratory test abnormalities as follows: ① platelet count ≤ 100 × 10⁹\u002FL; ② International Normalized Ratio (INR) ≥ 1.5; ③ total bilirubin (TBIL) \\> 2 × upper limit of normal (ULN); ④ alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2.5 × ULN; ⑤ serum creatinine (Scr) \\> 1.5 × ULN\n15. Patients with severe and unstable diseases of the mental, neurological, respiratory, digestive, renal, metabolic, immune, hematologic, or other systems, as well as malignant tumors, who are assessed by the investigator as unsuitable for participation in this clinical trial\n16. Presence of any contraindications listed in the package insert of ranibizumab injection (Lucentis®) or other anti-VEGF injections\n17. Suspected allergy to any study drug\n18. Pregnant or lactating females; males or females who plan to conceive within 30 days from signing the ICF to the end of the trial, or who cannot use effective contraceptive measures\n19. Participation in another interventional clinical trial within 3 months prior to randomization\n20. Other reasons deemed unsuitable for participation in this clinical trial by the investigator","85 Years",{"count":166,"type":20},450,[121],"The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.",[27],"2026-04-02",{"date":172,"type":37},"2026-04-08",{"date":174,"type":20},"2026-04-30",{"date":176,"type":20},"2031-12-31",{"name":178,"class":44},"Tasly Pharmaceutical Group Co., Ltd",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100423643","post-market-clinical-investigation-of-the-sing-imt-system-model-ng-si-imt-3x-in-patients-with-end-stage-age-related-macular-degeneration-100423643","NCT04796545","Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration","A Prospective, Multicenter Post-marketing Clinical Investigation of the SING IMT(TM) System, Model NG SI IMT 3X in Patients With Central Vision Impairment Associated With End-stage Age-related Macular Degeneration","Inclusion Criteria:\n\n1. Be 55 years of age or older.\n2. Have retinal findings of geographic atrophy or disciform scar with foveal involvement as determined by fluorescein angiography or OCT.\n3. Have evidence of cataract.\n4. Have best-corrected distance visual acuity (BCDVA) no better than 20\u002F80 (0.6 LogMAR) and no worse than 20\u002F800 (1.6 LogMAR) in both eyes.\n5. Have adequate peripheral vision in the eye not scheduled for surgery, assessed by observation of ambulation.\n6. Achieve at least a five-letter improvement on the ETDRS chart in the eye scheduled for surgery when using Samsara's 2.8X external telescope simulator (ETS, supplied separately).\n7. Have an ACD of at least 2.5 mm in the eye scheduled for surgery.\n8. Be willing to participate in a post-operative training program for the use of the NG SI IMT 3X implant.\n9. Review and sign the Independent Ethics Committee (IEC)-approved Informed Consent Form (ICF) prior to any study-related procedures being performed.\n10. Have adequate understanding of the local language to understand verbal and written subject information and be willing to comply with the study requirements.\n\nExclusion Criteria:\n\n1. Evidence of active choroidal neovascularization (CNV) on fluorescein angiography or OCT or were treated for CNV within the past six months.\n2. Any ophthalmic pathology that compromises the patient's peripheral vision in the fellow eye.\n3. A history of steroid-responsive rise in IOP, uncontrolled glaucoma, or preoperative IOP\\>22 mm Hg.\n4. Corneal guttata.\n5. Known sensitivity to post-operative medications.\n6. Significant communication impairment or severe neurological disorders.\n7. Have undergone previous intraocular or corneal surgery of any kind in the operative eye, including any type of surgery for either refractive or therapeutic purposes.\n8. An ocular condition that predisposes the patient to eye rubbing.\n9. Prior or expected ophthalmic-related surgery within 30 days preceding the NG SI IMT 3X implant surgery.\n10. Patients for whom the planned operative eye has:\n\n    * Myopia \\> 6.0 D\n    * Hyperopia \\> 4.0 D\n    * Axial length \\\u003C 21 mm\n    * Endothelial cell density \\\u003C 1600 cells per square mm\n    * Narrow angle, i.e., \\\u003C Schaffer grade 2.\n11. Inflammatory ocular disease.\n12. Cornea stromal or endothelial dystrophies, including guttata.\n13. Zonular weakness\u002Finstability of crystalline lens, or pseudoexfoliation.\n14. Diabetic retinopathy.\n15. Untreated retinal tears.\n16. Retinal vascular disease.\n17. Optic nerve disease.\n18. A history of retinal detachment.\n19. Retinitis pigmentosa.\n20. Intraocular tumor.\n21. Have received any investigational product within 30 days prior to study enrollment or be planning to participate in another investigation during the course of this study.\n22. Be an employee (or a relative of an employee) of the contract research organization (CRO) responsible for conducting the study, Sponsor, or Sponsor representative.\n23. Have a condition or be in a situation that, in the Investigator's opinion, may put the Subject at significant risk, may confound the study results, or may interfere significantly with the Subject's participation in the study.","55 Years",{"count":188,"type":20},76,[23],"The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD).\n\nEligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.",[27,69],[193,194,195,196,197],"Age Related Macular Degeneration","Dry AMD","End-stage age-related macular degeneration","Central vision impairment","Geographic atrophy","2026-02-05",{"date":200,"type":37},"2026-02-10",{"date":202,"type":37},"2022-09-13",{"date":204,"type":20},"2028-12",{"name":206,"class":44},"VisionCare, Inc.",13,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":79},"100481333","detection-and-management-of-sinusitis-in-a-single-center-prospective-cohort-of-patients-with-exudative-amd-sine-100481333","NCT05547633","Detection and Management of Sinusitis in a Single-center Prospective Cohort of Patients With Exudative AMD (SINE)","SINE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient followed and treated for at least 2 years for bilateral neovascular form of age-related macular degeneration (AMD)\n* At least one eye treated with ≥ 6 intravitreal injections during the year preceding preinclusion\n* Express consent to participate in the study\n* Affiliated with or beneficiary of a social security plan\n\nExclusion Criteria:\n\n* Persons referred to in articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of liberty by judicial or administrative decision, minors, and persons under legal protection: guardianship or curatorship).\n* Severe myopia (\\> 6 diopters)\n* Patient already being treated for acute or chronic sinusitis\n* History of central serous chorioretinopathy or diffuse retinal epitheliopathy","18 Years",{"count":217,"type":20},200,"An inflammatory component associated with AMD has been highlighted by genetic associations of predisposition to AMD, as well as by the recently demonstrated link between AMD and periodontitis.\n\nSome patients followed at the Fondation Adolphe de Rothschild Hospital for wet AMD seemed to show an improvement of neovascular activity (less need for intravitreal injections of anti-VEGF) after treatment of their sinusitis.\n\nThe investigators would therefore like to assess the link between AMD and sinusitis, an infection close to the site of AMD.",[27],"2025-12-03",{"date":222,"type":37},"2025-12-10",{"date":224,"type":37},"2023-01-20",{"date":226,"type":20},"2028-04",{"name":228,"class":229},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":53,"sex":16,"minAge":215,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":79},"100419253","project-amd-comprehensive-characterisation-of-age-related-macular-degeneration-and-its-progression-100419253","NCT04739319","Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression","Project AMD","Inclusion Criteria:\n\n1. 18 years of age or older; and\n2. either AMD (defined as having at least a medium druse \\>63 um), or having eyes with normal ageing changes (including small drusen ≤63 um) or no abnormalities as control participants\n\nExclusion Criteria:\n\n1. ocular or systemic conditions other than AMD that could compromise retinal assessment or assessment of AMD and its progression; or\n2. any participant with any mental or physical impairment that prevents them from signing an informed consent form or participating in this study.",{"count":238,"type":20},2500,"Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD. This proposed project is a prospective, observational study that seeks to to understand the underlying aetiology of AMD, factors associated with differences between age-related macular degeneration (AMD) phenotypes or severities, or between AMD and healthy individuals. It also seeks to understand the natural history of AMD progression and the factors associated with the rate of progression. In this project, the disease phenotype, genotype and severity and rate of progression will be determined based on non-invasive clinical imaging or functional assessment of the retina, from obtaining biological samples from the participants, or from patient-reported outcomes.",[193,241,27,242],"Geographic Atrophy","Age-related Macular Degeneration",[193,241,244,245],"Drusen","Macular disease","2024-02-07",{"date":248,"type":37},"2024-02-09",{"date":250,"type":37},"2021-02-02",{"date":252,"type":20},"2040-11",{"name":254,"class":108},"Center for Eye Research Australia"]